Published in Behav Neurosci on October 01, 2008
Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction (2010) 2.04
Working memory deficits predict short-term smoking resumption following brief abstinence. Drug Alcohol Depend (2009) 1.53
Genetic variability in nicotinic acetylcholine receptors and nicotine addiction: converging evidence from human and animal research. Behav Brain Res (2008) 1.14
Strain-dependent effects of acute, chronic, and withdrawal from chronic nicotine on fear conditioning. Behav Genet (2011) 1.03
Developmental effects of acute, chronic, and withdrawal from chronic nicotine on fear conditioning. Neurobiol Learn Mem (2012) 1.01
Cognitive function during nicotine withdrawal: Implications for nicotine dependence treatment. Neuropharmacology (2013) 0.98
Substance abuse, memory, and post-traumatic stress disorder. Neurobiol Learn Mem (2013) 0.97
Hippocampal nAChRs mediate nicotine withdrawal-related learning deficits. Eur Neuropsychopharmacol (2009) 0.96
Nicotine withdrawal disrupts new contextual learning. Pharmacol Biochem Behav (2008) 0.95
Cellular, molecular, and genetic substrates underlying the impact of nicotine on learning. Neurobiol Learn Mem (2013) 0.93
The duration of nicotine withdrawal-associated deficits in contextual fear conditioning parallels changes in hippocampal high affinity nicotinic acetylcholine receptor upregulation. Neuropharmacology (2012) 0.90
Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats. Neuropsychopharmacology (2012) 0.88
Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal. Expert Opin Drug Discov (2014) 0.86
Varenicline blocks β2*-nAChR-mediated response and activates β4*-nAChR-mediated responses in mice in vivo. Nicotine Tob Res (2012) 0.86
A single administration of low-dose varenicline saturates α4β2* nicotinic acetylcholine receptors in the human brain. Neuropsychopharmacology (2012) 0.85
The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice. Behav Brain Res (2011) 0.85
Divergent functional effects of sazetidine-a and varenicline during nicotine withdrawal. Neuropsychopharmacology (2013) 0.84
Mouse model predicts effects of smoking and varenicline on event-related potentials in humans. Nicotine Tob Res (2010) 0.81
Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia. Psychopharmacology (Berl) (2013) 0.80
Donepezil, an acetylcholinesterase inhibitor, attenuates nicotine self-administration and reinstatement of nicotine seeking in rats. Addict Biol (2012) 0.80
Dissociation of tolerance and nicotine withdrawal-associated deficits in contextual fear. Brain Res (2014) 0.79
Cholinergic regulation of fear learning and extinction. J Neurosci Res (2016) 0.78
Negative affective states and cognitive impairments in nicotine dependence. Neurosci Biobehav Rev (2015) 0.78
Transdisciplinary Tobacco Use Research Centers: research achievements and future implications. Nicotine Tob Res (2009) 0.78
Association of abstinence-induced alterations in working memory function and COMT genotype in smokers. Psychopharmacology (Berl) (2013) 0.77
Mouse models for studying genetic influences on factors determining smoking cessation success in humans. Ann N Y Acad Sci (2012) 0.77
Donepezil reverses nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6J mice. Behav Neurosci (2014) 0.77
ABT-089, but not ABT-107, ameliorates nicotine withdrawal-induced cognitive deficits in C57BL6/J mice. Behav Pharmacol (2015) 0.77
Involvement of neuronal β2 subunit-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal: implications for pharmacotherapies. J Clin Pharm Ther (2014) 0.76
Targeting the Cholinergic System to Develop a Novel Therapy for Huntington's Disease. J Huntingtons Dis (2016) 0.75
Withdrawal From Chronic Nicotine Reduces Thyroid Hormone Levels and Levothyroxine Treatment Ameliorates Nicotine Withdrawal-Induced Deficits in Hippocampus-Dependent Learning in C57BL/6J Mice. Nicotine Tob Res (2014) 0.75
Actual causes of death in the United States, 2000. JAMA (2004) 44.38
Annual smoking-attributable mortality, years of potential life lost, and productivity losses--United States, 1997-2001. MMWR Morb Mortal Wkly Rep (2005) 8.10
Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA (2006) 5.19
Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addition. N Engl J Med (1988) 4.98
Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol (2006) 3.84
Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med (2006) 3.30
A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol (1992) 3.20
Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther (1988) 3.05
Crouching as an index of fear. J Comp Physiol Psychol (1969) 3.00
Symptoms of tobacco withdrawal. A replication and extension. Arch Gen Psychiatry (1991) 2.51
Effects of smoking and smoking abstinence on cognition in adolescent tobacco smokers. Biol Psychiatry (2005) 2.36
Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas. J Neurosci (2003) 2.35
Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. J Neurosci (1992) 2.29
Why people smoke. BMJ (2004) 2.09
Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol (1993) 2.02
Smoking after nicotine deprivation enhances cognitive performance and decreases tobacco craving in drug abusers. Nicotine Tob Res (1999) 2.00
Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health (2006) 1.91
Translational research in medication development for nicotine dependence. Nat Rev Drug Discov (2007) 1.81
Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities. Addiction (1994) 1.80
Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J Pharmacol Exp Ther (1999) 1.73
Working memory in cigarette smokers: comparison to non-smokers and effects of abstinence. Addict Behav (2005) 1.69
Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover. Mol Pharmacol (1994) 1.68
Withdrawal from chronic nicotine administration impairs contextual fear conditioning in C57BL/6 mice. J Neurosci (2005) 1.68
Circadian blood nicotine concentrations during cigarette smoking. Clin Pharmacol Ther (1982) 1.60
Nicotine enhancement of contextual fear conditioning. Behav Brain Res (1999) 1.57
Rodent model of nicotine abstinence syndrome. Pharmacol Biochem Behav (1992) 1.54
Pharmacotherapy for nicotine dependence. CA Cancer J Clin (2005) 1.54
Nicotine enhances contextual fear conditioning in C57BL/6J mice at 1 and 7 days post-training. Neurobiol Learn Mem (2003) 1.49
Hippocampal alpha4beta2 nicotinic acetylcholine receptor involvement in the enhancing effect of acute nicotine on contextual fear conditioning. J Neurosci (2007) 1.48
Time course study of the effects of chronic nicotine infusion on drug response and brain receptors. J Pharmacol Exp Ther (1985) 1.39
Human alpha 7 acetylcholine receptor: cloning of the alpha 7 subunit from the SH-SY5Y cell line and determination of pharmacological properties of native receptors and functional alpha 7 homomers expressed in Xenopus oocytes. Mol Pharmacol (1994) 1.39
Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin Emerg Drugs (2006) 1.35
Subtype-selective up-regulation by chronic nicotine of high-affinity nicotinic receptors in rat brain demonstrated by receptor autoradiography. J Pharmacol Exp Ther (2003) 1.35
Economic costs of substance abuse, 1995. Proc Assoc Am Physicians (1999) 1.34
Agonist-induced up-regulation of alpha4beta2 nicotinic acetylcholine receptors in M10 cells: pharmacological and spatial definition. Mol Pharmacol (1998) 1.34
Role of neuronal nicotinic receptors in the effects of nicotine and ethanol on contextual fear conditioning. Neuroscience (2004) 1.33
Chronic nicotine exposure differentially affects the function of human alpha3, alpha4, and alpha7 neuronal nicotinic receptor subtypes. J Pharmacol Exp Ther (1997) 1.29
Increases in hyperactive-impulsive symptoms predict relapse among smokers in nicotine replacement therapy. J Subst Abuse Treat (2005) 1.28
Nicotine dependence: studies with a laboratory model. Pharmacol Biochem Behav (2001) 1.23
Chronic nicotine treatment up-regulates alpha3 and alpha7 acetylcholine receptor subtypes expressed by the human neuroblastoma cell line SH-SY5Y. Mol Pharmacol (1997) 1.21
Impact of smoking abstinence on working memory neurocircuitry in adolescent daily tobacco smokers. Psychopharmacology (Berl) (2007) 1.18
Temporal change in human nicotinic acetylcholine receptor after smoking cessation: 5IA SPECT study. J Nucl Med (2007) 1.17
Beta2 subunit containing acetylcholine receptors mediate nicotine withdrawal deficits in the acquisition of contextual fear conditioning. Neurobiol Learn Mem (2007) 1.16
Nicotine and hippocampus-dependent learning: implications for addiction. Mol Neurobiol (2006) 1.09
Sensitization of the mesoaccumbens dopamine response to nicotine. Pharmacol Biochem Behav (1998) 1.06
Nicotine dependence and tolerance in man: pharmacokinetic and pharmacodynamic investigations. Prog Brain Res (1989) 1.06
Overview: a comparison of withdrawal symptoms from different drug classes. Addiction (1994) 1.05
Nicotine-induced up-regulation and desensitization of alpha4beta2 neuronal nicotinic receptors depend on subunit ratio. J Biol Chem (2004) 1.05
Bupropion dose-dependently reverses nicotine withdrawal deficits in contextual fear conditioning. Pharmacol Biochem Behav (2007) 0.99
Effects of prolonged nicotinic ligand exposure on function of heterologously expressed, human alpha4beta2- and alpha4beta4-nicotinic acetylcholine receptors. J Pharmacol Exp Ther (2003) 0.97
Atomoxetine reverses nicotine withdrawal-associated deficits in contextual fear conditioning. Neuropsychopharmacology (2007) 0.96
Regulation of nicotinic receptors in the brain of mice withdrawn from chronic oral nicotine treatment. Naunyn Schmiedebergs Arch Pharmacol (1998) 0.94
Nicotine and non-nicotine smoking cessation pharmacotherapies. Cardiol Rev (2006) 0.91
Sensitization of cortical acetylcholine release by repeated administration of nicotine in rats. Psychopharmacology (Berl) (2002) 0.91
Dissociation of the apparent relationship between nicotine tolerance and up-regulation of nicotinic receptors. Brain Res Bull (1990) 0.87
Effect of tobacco withdrawal on sustained attention. Addict Behav (1989) 0.86
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol (2002) 4.38
Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol (2004) 3.88
Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry (2008) 3.12
Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. Ann Intern Med (2010) 2.94
Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry (2008) 2.29
Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A (2003) 2.29
Association of attention-deficit/hyperactivity disorder symptoms with levels of cigarette smoking in a community sample of adolescents. J Am Acad Child Adolesc Psychiatry (2002) 2.19
Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol (2002) 2.13
Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum Mol Genet (2008) 2.12
Neural substrates of abstinence-induced cigarette cravings in chronic smokers. J Neurosci (2007) 2.11
Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet (2009) 2.07
All in the family: evaluation of the process and content of sisters' communication about BRCA1 and BRCA2 genetic test results. Am J Med Genet (2002) 2.05
Gender differences in acute tobacco withdrawal: effects on subjective, cognitive, and physiological measures. Exp Clin Psychopharmacol (2007) 1.94
A randomized controlled trial of financial incentives for smoking cessation. Cancer Epidemiol Biomarkers Prev (2006) 1.93
Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav (2008) 1.90
New lower nicotine cigarettes can produce compensatory smoking and increased carbon monoxide exposure. Drug Alcohol Depend (2006) 1.85
Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc Natl Acad Sci U S A (2009) 1.76
The use of race variables in genetic studies of complex traits and the goal of reducing health disparities: a transdisciplinary perspective. Am Psychol (2005) 1.71
Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine. Mol Neurobiol (2008) 1.71
Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology (2003) 1.70
Cigarette smoking practices among American college students: review and future directions. J Am Coll Health (2004) 1.69
A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Health Psychol (2002) 1.69
Withdrawal from chronic nicotine administration impairs contextual fear conditioning in C57BL/6 mice. J Neurosci (2005) 1.68
Relationship between education and delay discounting in smokers. Addict Behav (2004) 1.65
Assessing dimensions of nicotine dependence: an evaluation of the Nicotine Dependence Syndrome Scale (NDSS) and the Wisconsin Inventory of Smoking Dependence Motives (WISDM). Nicotine Tob Res (2008) 1.62
Medication screening for smoking cessation: a proposal for new methodologies. Psychopharmacology (Berl) (2005) 1.62
Barriers to translating emerging genetic research on smoking into clinical practice. Perspectives of primary care physicians. J Gen Intern Med (2005) 1.54
Working memory deficits predict short-term smoking resumption following brief abstinence. Drug Alcohol Depend (2009) 1.53
Non-replication of genetic association studies: is DAT all, folks? Nicotine Tob Res (2002) 1.50
Interacting effects of genetic predisposition and depression on adolescent smoking progression. Am J Psychiatry (2004) 1.50
CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol Psychiatry (2007) 1.48
Hippocampal alpha4beta2 nicotinic acetylcholine receptor involvement in the enhancing effect of acute nicotine on contextual fear conditioning. J Neurosci (2007) 1.48
Colon cancer screening practices following genetic testing for hereditary nonpolyposis colon cancer (HNPCC) mutations. Arch Intern Med (2004) 1.48
Parent-child factors and their effect on communicating BRCA1/2 test results to children. Patient Educ Couns (2002) 1.47
CHRNA4 and tobacco dependence: from gene regulation to treatment outcome. Arch Gen Psychiatry (2007) 1.44
Comparison between two measures of delay discounting in smokers. Exp Clin Psychopharmacol (2003) 1.42
Food hedonics and reinforcement as determinants of laboratory food intake in smokers. Physiol Behav (2004) 1.41
Initial nicotine sensitivity in humans as a function of impulsivity. Psychopharmacology (Berl) (2008) 1.40
The effects of DHBE and MLA on nicotine-induced enhancement of contextual fear conditioning in C57BL/6 mice. Psychopharmacology (Berl) (2005) 1.39
Facilitating transdisciplinary research: the experience of the transdisciplinary tobacco use research centers. Nicotine Tob Res (2003) 1.39
Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol (2003) 1.38
Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers. Biol Psychiatry (2010) 1.38
Smoking topography predicts abstinence following treatment with nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev (2004) 1.38
An association of CYP2A6 genotype and smoking topography. Nicotine Tob Res (2007) 1.37
Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin Emerg Drugs (2006) 1.35
Behavioral consequences of testing for obesity risk. Cancer Epidemiol Biomarkers Prev (2005) 1.35
Relation between food reinforcement and dopamine genotypes and its effect on food intake in smokers. Am J Clin Nutr (2004) 1.34
Individual differences in nicotine intake per cigarette. Cancer Epidemiol Biomarkers Prev (2003) 1.32
Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci U S A (2011) 1.29
Increases in hyperactive-impulsive symptoms predict relapse among smokers in nicotine replacement therapy. J Subst Abuse Treat (2005) 1.28
Influence of methylphenidate on eating in obese men. Obes Res (2004) 1.27
Association of retrospective early smoking experiences with prospective sensitivity to nicotine via nasal spray in nonsmokers. Nicotine Tob Res (2008) 1.27
Evidence for endogenous formation of N'-nitrosonornicotine in some long-term nicotine patch users. Nicotine Tob Res (2009) 1.27
Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res (2007) 1.26
Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenet Genomics (2013) 1.24
Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiol Biomarkers Prev (2005) 1.24
Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling. Nicotine Tob Res (2004) 1.24
Treating tobacco dependence in women. J Womens Health (Larchmt) (2007) 1.23
Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood. Behav Pharmacol (2008) 1.22
Experimental evaluation of antitobacco PSAs: effects of message content and format on physiological and behavioral outcomes. Nicotine Tob Res (2009) 1.21
Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob Res (2007) 1.21
Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion. Nicotine Tob Res (2005) 1.20
Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol Psychiatry (2006) 1.18
Characteristics of cancer patients entering a smoking cessation program and correlates of quit motivation: implications for the development of tobacco control programs for cancer patients. Psychooncology (2004) 1.17
Convergent evidence that choline acetyltransferase gene variation is associated with prospective smoking cessation and nicotine dependence. Neuropsychopharmacology (2010) 1.17
Reduced prefrontal and temporal processing and recall of high "sensation value" ads. Neuroimage (2009) 1.17
Beta2 subunit containing acetylcholine receptors mediate nicotine withdrawal deficits in the acquisition of contextual fear conditioning. Neurobiol Learn Mem (2007) 1.16
Facilitating clinical implementation of pharmacogenomics. JAMA (2011) 1.16
The effect of smoking cues in antismoking advertisements on smoking urge and psychophysiological reactions. Nicotine Tob Res (2009) 1.15
Nicotine vaccines: will smokers take a shot at quitting? Nicotine Tob Res (2010) 1.15
Evaluating smokers' reactions to advertising for new lower nicotine quest cigarettes. Psychol Addict Behav (2006) 1.15
Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology (2011) 1.15
Genetic variability in nicotinic acetylcholine receptors and nicotine addiction: converging evidence from human and animal research. Behav Brain Res (2008) 1.14
Nicotine enhances both foreground and background contextual fear conditioning. Neurosci Lett (2005) 1.13
Pharmacogenetics and nicotine addiction treatment. Pharmacogenomics (2005) 1.13
Narrative Health Communication and Behavior Change: The Influence of Exemplars in the News on Intention to Quit Smoking. J Commun (2012) 1.13
The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. Cancer Epidemiol Biomarkers Prev (2013) 1.13
Associations between Cloninger's temperament dimensions and acute tobacco withdrawal. Addict Behav (2007) 1.13
Primary care physicians' willingness to offer a new genetic test to tailor smoking treatment, according to test characteristics. Nicotine Tob Res (2008) 1.12
Identification of pharmacogenetic markers in smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet (2008) 1.12
A randomized pilot study of cognitive-behavioral therapy versus basic health education for smoking cessation among cancer patients. Ann Behav Med (2005) 1.12
Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet Genomics (2005) 1.11
beta2 subunit-containing nicotinic receptors mediate the enhancing effect of nicotine on trace cued fear conditioning in C57BL/6 mice. Psychopharmacology (Berl) (2006) 1.11
Variability in initial nicotine sensitivity due to sex, history of other drug use, and parental smoking. Drug Alcohol Depend (2008) 1.10
Nicotine enhances context learning but not context-shock associative learning. Behav Neurosci (2008) 1.09
Genetics and smoking behavior. Curr Psychiatry Rep (2007) 1.09
Can the blind see? Participant guess about treatment arm assignment may influence outcome in a clinical trial of bupropion for smoking cessation. J Subst Abuse Treat (2007) 1.08
Smoking cues, argument strength, and perceived effectiveness of antismoking PSAs. Nicotine Tob Res (2011) 1.07
Reduced nicotine reward in obesity: cross-comparison in human and mouse. Psychopharmacology (Berl) (2005) 1.05
Breast and ovarian cancer screening practices in healthy women with a strong family history of breast or ovarian cancer. Breast Cancer Res Treat (2002) 1.04
Dopamine genes and nicotine dependence in treatment-seeking and community smokers. Neuropsychopharmacology (2009) 1.04
Strain-dependent effects of acute, chronic, and withdrawal from chronic nicotine on fear conditioning. Behav Genet (2011) 1.03
Do small lapses predict relapse to smoking behavior under bupropion treatment? Nicotine Tob Res (2004) 1.03
The STAGE cohort: a prospective study of tobacco use among Swedish twins. Nicotine Tob Res (2008) 1.02
Neuronal nicotinic acetylcholine receptors: involvement in Alzheimer's disease and schizophrenia. Behav Cogn Neurosci Rev (2002) 1.02
Developmental effects of acute, chronic, and withdrawal from chronic nicotine on fear conditioning. Neurobiol Learn Mem (2012) 1.01
Intergenerational transmission of tobacco use and dependence: a transdisciplinary perspective. Nicotine Tob Res (2003) 1.01
Smoking in response to negative mood in men versus women as a function of distress tolerance. Nicotine Tob Res (2012) 1.00
Predictors of attendance in a randomized clinical trial of nicotine replacement therapy with behavioral counseling. Drug Alcohol Depend (2003) 1.00
Interactive effects of ethanol and nicotine on learning in C57BL/6J mice depend on both dose and duration of treatment. Psychopharmacology (Berl) (2007) 0.99